CD276 and ovarian carcinoma: The dual blockade of PD-1 and CTLA-4, conducted to simultaneously inhibit CD276, can help in inhibiting the activation of T cells and cytokine secretion, thereby also downregulating LAG-3 expression and improving antitumor immunity to achieve inhibition of ovarian cancer metastasis.